One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Youth gender services: a new model for regional care
doi : 10.1016/S2213-8587(22)00224-8
Volume 10, Issue 9, September 2022, Page 609
Isseki nich� (one stone, two birds): a dual incretin receptor agonist for type 2 diabetes
Ryan J Jalleh a b d f, Christopher K Rayner a b e, Karen L Jones a b c, Michael Horowitz a b c d
Blood pressure control according to type 2 diabetes status
doi : 10.1016/S2213-8587(22)00191-7
Volume 10, Issue 9, September 2022, Pages 612-613
The burden of diabetes in the Americas
doi : 10.1016/S2213-8587(22)00196-6
Volume 10, Issue 9, September 2022, Pages 613-614
Hyperglycaemia management in non-critical care settings: guidelines in focus
Mark E Molitch a
A global plastics treaty to protect endocrine health
doi : 10.1016/S2213-8587(22)00216-9
Volume 10, Issue 9, September 2022, Pages 616-618
Madelung's disease in a rare 14th century Franco-Flemish woolen tapestry
doi : 10.1016/S2213-8587(22)00213-3
Volume 10, Issue 9, September 2022, Pages 619-620
Mar�a José Redondo: rethinking type 1 diabetes
doi : 10.1016/S2213-8587(22)00211-X
Volume 10, Issue 9, September 2022, Page 621
Food security and nutrition in the world
doi : 10.1016/S2213-8587(22)00220-0
Volume 10, Issue 9, September 2022, Page 622
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–83
doi : 10.1016/S2213-8587(22)00194-2
Volume 10, Issue 9, September 2022, Page e9
Correction to Lancet Diabetes Endocrinol 2022; 10: 612–13
doi : 10.1016/S2213-8587(22)00222-4
Volume 10, Issue 9, September 2022, Page e9
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
Prof Nobuya Inagaki MD a, Masakazu Takeuchi PhD b, Tomonori Oura MSc b, Takeshi Imaoka MD b, Prof Yutaka Seino MD c
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial
Prof Takashi Kadowaki MD a, Rina Chin MD b, Akichika Ozeki PhD c, Takeshi Imaoka MD c, Prof Yoshihiro Ogawa MD d
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis
doi : 10.1016/S2213-8587(22)00172-3
Volume 10, Issue 9, September 2022, Pages 645-654
Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
doi : 10.1016/S2213-8587(22)00186-3
Volume 10, Issue 9, September 2022, Pages 655-667
Polycystic ovary syndrome
Anju E Joham PhD a b, Robert J Norman MD c, Elisabet Stener-Victorin PhD d, Richard S Legro MD e, Stephen Franks MD f, Lisa J Moran PhD a, Jacqueline Boyle PhD a, Prof Helena J Teede PhD a b
